CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the first quarter ended March 31, 2011. “We are actively moving our pain and inflammation-focused portfolio forward during 2011,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “We plan to initiate a Phase 2b clinical trial of Synavive™ for rheumatoid arthritis in the second quarter, and we identified promising Ion channel leads to move into clinical development for pain in the second half of the year.”
